AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today that the Company entered into a noteworthy sales contract in mid-August 2020 with Beijing Yuan Jian Health Management Co., Ltd. in China for the Company’s newly launched immunology test, AnPac Defense Medical Examination (ADME). Beijing Yuan Jian Health Management has already been a client of AnPac for the past two years. The contract has a duration of 14 months and includes 20,000 paid ADME tests, with the expectation that the test is to be offered to end customers at multiple locations in China.
This new immunology test, especially its design, algorithm and its simple scoring system, is based on the learning and intellectual property of AnPac’s cancer differentiation analysis technology (CDA), while its specific immunology related components, such as data around white blood cells, T cells and complements are already clinically validated and regulatory approved tests.
AnPac Bio’s CEO, Dr. Chris Yu, remarked, “This significant sales contract for our new immunology test ADME showed that our new product initiative and launch has received positive response from the market and our customers. We believe that this new product propel the company forward in exhibiting strong future growth.”
About Beijing Yuan Jian Health Management Co., Ltd.
Beijing Yuan Jian Health Management Co., Ltd. is a Chinese health management firm with a focus on health care management. Its team consists of well-known experts and professionals in the fields of health care management and medicine, and it has collaborated with various well-known academic and medical institutions including universities, hospitals and other healthcare organizations in China and the U.S.
About AnPac Bio
AnPac Bio is a biotechnology company focused on early cancer screening and detection, with 128 issued patents as of June 30, 2020. With two certified clinical laboratories in China and one CLIA and CAP accredited clinical laboratory in the United States, AnPac Bio performs a suite of cancer screening and detection tests, including CDA (Cancer Differentiation Analysis), bio-chemical, immunological, and genomics tests. According to Frost & Sullivan, AnPac Bio ranked third worldwide and first in China among companies offering next-generation early cancer screening and detection technologies in terms of the number of clinical samples for cancer screening and detection, based on approximately 41,700 clinical samples as at May 2020. AnPac Bio’s CDA technology platform has been shown in retrospective validation studies to be able to detect the risk of over 20 different cancer types with high sensitivity and specificity.